Cargando…

Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation

Lag-3 has emerged as an important molecule in T cell biology. We investigated the role of Lag-3 in conventional T cell (Tcon) and regulatory T cell (Treg) function in murine GVHD with the hypothesis that Lag-3 engagement diminishes alloreactive T cell responses after bone marrow transplantation. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sega, Emanuela I., Leveson-Gower, Dennis B., Florek, Mareike, Schneidawind, Dominik, Luong, Richard H., Negrin, Robert S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903521/ https://www.ncbi.nlm.nih.gov/pubmed/24475140 http://dx.doi.org/10.1371/journal.pone.0086551

Ejemplares similares

Freeze and Thaw of CD4(+)CD25(+)Foxp3(+) Regulatory T Cells Results in Loss of CD62L Expression and a Reduced Capacity to Protect against Graft-versus-Host Disease
por: Florek, Mareike, et al.
Publicado: (2015)

Editorial: Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation
por: Schneidawind, Dominik, et al.
Publicado: (2020)

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors
por: Cruz, David, et al.
Publicado: (2023)

Allogeneic Transplantation for Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2010)

Lymphocyte Activation Gene-3 (LAG-3) Negatively Regulates Environmentally-Induced Autoimmunity
por: Jha, Vibha, et al.
Publicado: (2014)

Regulatory T Cells in Allogeneic Stem Cell Transplantation
por: Michael, Maria, et al.
Publicado: (2013)

Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation
por: Simonetta, Federico, et al.
Publicado: (2017)

Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis
por: Saleh, Ramy R., et al.
Publicado: (2019)

Biocatalytic Friedel‐Crafts Reactions
por: Leveson‐Gower, Reuben B., et al.
Publicado: (2022)

Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma
por: Gebauer, Florian, et al.
Publicado: (2020)

Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo
por: Durham, Nicholas M., et al.
Publicado: (2014)

Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma
por: Zhang, Yu, et al.
Publicado: (2018)

Lymphocyte Activation Gene 3 (Lag3) Contributes to α-Synucleinopathy in α-Synuclein Transgenic Mice
por: Gu, Hao, et al.
Publicado: (2021)

Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications
por: Zhao, Lishu, et al.
Publicado: (2022)

LAG-3, a novel lymphocyte activation gene closely related to CD4
Publicado: (1990)

Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation
por: Mavers, Melissa, et al.
Publicado: (2017)

LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells
por: Lino, Andreia C., et al.
Publicado: (2018)

Understanding LAG-3 Signaling
por: Chocarro, Luisa, et al.
Publicado: (2021)

Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression
por: Liu, Yingjun, et al.
Publicado: (2018)

Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas
por: Arolt, Christoph, et al.
Publicado: (2020)

Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells
por: Schmid, Hannes, et al.
Publicado: (2021)

Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis
por: Slevin, Stephanie M, et al.
Publicado: (2020)

Bridging Strategies to Allogeneic Transplant for Older AML Patients
por: Hecker, Judith, et al.
Publicado: (2018)

An IL-27/Lag3 axis enhances Foxp3(+) regulatory T cell suppressive function and therapeutic efficacy
por: Do, Jeong-su, et al.
Publicado: (2015)

Specific lysis of allogeneic cells after activation of CD3- lymphocytes in mixed lymphocyte culture
Publicado: (1988)

LAG3’s Enigmatic Mechanism of Action
por: Graydon, Colin G., et al.
Publicado: (2021)

Overcoming the LAG3 phase problem
por: Petersen, Jan, et al.
Publicado: (2022)

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Clinicopathological significance and prognostic role of LAG3 + tumor-infiltrating lymphocytes in colorectal cancer; relationship with sidedness
por: Tavana, Shirin, et al.
Publicado: (2023)

LAG-3(+) tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients
por: Hu, Guoming, et al.
Publicado: (2023)

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
por: Atkinson, Victoria, et al.
Publicado: (2020)

Unlocking Iminium Catalysis in Artificial Enzymes to Create a Friedel–Crafts Alkylase
por: Leveson-Gower, Reuben B., et al.
Publicado: (2021)

Tandem Friedel‐Crafts‐Alkylation‐Enantioselective‐Protonation by Artificial Enzyme Iminium Catalysis
por: Leveson‐Gower, Reuben B., et al.
Publicado: (2022)

Drug Lag and Key Regulatory Barriers in the Emerging Markets
por: Wileman, Harriet, et al.
Publicado: (2010)

A Case of Acute Lymphocytic Leukaemia with t(3;13) and Central Nervous System Leukemia after Allogenic Cord Blood Transplantation
por: Li, Xiaofan, et al.
Publicado: (2019)

Allogeneic Hematopoietic Cell Transplantation in the Treatment of Chronic Lymphocytic Leukemia: Why and When?
por: Delioukina, Maria L., et al.
Publicado: (2010)

Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
por: Pavletic, ZS, et al.
Publicado: (1998)

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience
por: Shadman, Mazyar, et al.
Publicado: (2019)

The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review
por: Puckrin, Robert, et al.
Publicado: (2023)

T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity
por: Cemerski, Saso, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tbnh174ge2o5hm129tlcf78lld